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ABSTRACT 
Background: Insulin sensitizer drugs such as metformin has suggested giving in 
metabolic syndrome patient and NAFLD, which both pathogeneses were insulin 
resistance. Angiotensin II receptor blocker (ARB), anti-hypertension drugs, has the 
similar properties to improve regulation of Proliferator-Activated Receptor Gama 
(PPARɤ). This aim of the study is to prove the improvement of insulin resistance 
which examined by HOMA-IR method on metabolic syndrome patient with NAFLD 
after receiving metformin and valsartan medication.  
Method: This study was conducted to the patient in Endocrinology Clinic Sardjito 
General Hospital aged 35-36 years who meet diagnostic criteria for metabolic syndrome 
based on the IDF in 2006 and NAFLD. Convenience sampling method is done for 11 
months (May 2012 – March 2013) and was expected sample size 35. HOMA-IR 
examination made before and after administration of metformin and valsartan for 12 
weeks. Cut off value for HOMA –IR on pathological metabolic syndrome and NAFLD 
was ≥ 2. Medical and Health Research Ethics Committee (MHREC) Faculty of 
Medicine Universitas Gadjah Mada approved this study protocol. 
Result: Subject of study retrieved 15 (43%), six males (40%) and nine females (60%) 
aged 43-63 years old. Median HOMA-IR baseline was 2.8 (0.6-14.5) and at the end of 
therapy was 3.8 (1.72-14.1). Eleven (74%) have increased HOMA-IR value and four 
(26%) experience declined but none of them reach the value below 2. In general clinical 
improvement occurs in the form of AST and ALT reduction but not statistically 
significant.  
Conclusion: This study does not prove that administration of metformin and valsartan 
in-patient with metabolic syndrome with NAFLD would improve insulin resistance 
assessed by the HOMA-IR method. 
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ABSTRAK 
Latar belakang: Obat insulin sensitizer semacam metformin disarankan untuk diberikan kepada 
pasien sindrom metabolik dan NAFLD, yang keduanya adalah patogenesis dengan resistensi insulin. 
Angiotensin II receptor blocker (ARB), obat anti hipertensi, memiliki ciri untuk memperbaiki 
regulasi dari Proliferator-Activated Receptor Gama (PPARɤ).  
Tujuan: Tujuan dari penelitian ini adalah untuk membuktikan penyempurnaan resistensi insulin 
yang di uji menggunakan metode HOMA-IR pada pasien sindrom metabolik dengan NAFLD 
setelah menerima pengobatan metformin dan valsartan.  
Metode: Penelitian ini dilakukan pada pasien di klinik endokrinologi rumah sakit dr. Sardjito 
yang berumur 35-36 tahun serta memenuhi kriteria diagnostik untuk sindrom metabolik berdasar 
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IDF 2016 dan NAFLD. Metode sampling dilakukan selama 11 bulan (Mei 2012-Maret 2013) 
dan diharapkan ukuran sampel 35. Uji HOMA-IR sebelum dan sesudah pemberian metformin dan 
valsartan untuk 12 minggu. Pemotongan nilai untuk HOMA-IR patologi sindrom metabolik dan 
NAFLD ≥ 2. Komisi Etik Medis dan Kesehatan (MHREC) Fakultas Kedokteran Universitas 
Gadjah Mada telah menyetujui penelitian ini. 
Hasil: Subjek penelitian diambil sebanyak 15 (43%), enam laki-laki (40%) dan sembilan 
perempuan (60%) berusia 43-63 tahun. Garis dasar Median HOMA-IR adalah 2,8 (0,6-14,5) 
dan pada akhir terapi adalah 3,8 (1,72-14,1). Sebelas (74%) telah meningkatkan vaton HOMA-
IR dan empat (26%) pengalaman dalam bentuk pengurangan AST dan ALT namun tidak 
signifikan secara statistik. 
Kesimpulan: NAFLD akan memperbaiki resistensi insulin yang dinilai dengan metode 
HOMA-IR. 
 
Kata kunci: Metformin, valsartan, sindrom metabolik, NAFLD, HOMA-IR 
 
Introduction 
Metabolic syndrome is a 
clustering of health problems that are 
increasing the risk of cardiovascular 
disease. One clinical condition is also 
closely linked to the metabolic 
syndrome is Non-Alcoholic Fatty Liver 
Disease (NAFLD). Some researchers 
put NAFLD as a component of 
metabolic syndrome, other researchers 
think that NAFLD is a manifestation of 
the metabolic syndrome in the liver.1,2 
According to pathophysiologic 
considerations, the association of 
clinical and laboratory examination 
concluded that the central role of 
insulin resistance in the pathogenesis of 
the metabolic syndrome and NAFLD.3 
This understanding is a major 
reason utilization of insulin sensitizer 
drugs such as metformin and a 
thiazolidinedione for the therapy. 
Norberto et al, in a systematic review 
article, concludes insulin sensitizer 
therapy on NAFLD would improve 
insulin resistance and function liver.4 
Caldwell et al. (2006) in his review 
states that the provision of a 
thiazolidinedione in NAFLD shown to 
reduce liver fat and reduced evidence of 
cellular injury liver.5 
Patients with the chronic liver 
disease often occur activation of the 
renin-angiotensin system (RAS), so that 
the therapy of hypertension in 
metabolic syndrome components with 
NAFLD have drugs known as 
angiotensin II receptor blockers (ARBs) 
and angiotensin-converting enzyme 
inhibitor (ACEI). Another advantage of 
these drugs is their ant fibrotic 
characteristics by reducing the liver 
stellate cell proliferation and 
improvement of insulin resistance was 
assessed by Homeostasis Model 
Assessment-Insulin resistance (HOMA-
IR).6,7 The validity of this study is 
limited because of the number of 
subjects of the study. 
This study aims to demonstrate that 
administration of metformin and 
valsartan in patients with NAFLD 
metabolic syndrome will improve 
insulin resistance were examined with 
the HOMA-IR method. 
 
Materials and Methods 
This study uses a before-after 
design and uses convenience sampling, 
conducted at the Polyclinic Internal 
Medicine Endocrinology division of 
Sardjito General Hospital from May 
2012 to March 2013. Patients were in 
accordance with the criteria for 
diagnosis of metabolic syndrome (IDF 
2006) and NAFLD based on non-
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invasive examination. Include as a 
subject until the deadline of the study. 
The sample size expected to be 
calculate from the formula of two 
groups of numerical data.8 Based on the 
calculation, required sample size is 35 
subjects. 
Patients who met the inclusion 
and exclusion criteria were given an 
explanation of the purpose, benefits 
and the course of the study and signed 
informed consent. Then   recorded the 
patient characteristics such as age, 
gender, medical history, weight, height, 
blood pressure, body mass index, waist 
and hip circumference, long-suffering 
from diabetes (if diabetes mellitus) and 
acquired the last therapy. Do washout 
of metformin and valsartan at least 2 
weeks, and fasting blood samples to 
obtain the initial value of HOMA IR. 
Patients were given metformin 
and valsartan therapy treatment for 12 
weeks. Metformin was started at a dose 
of 500 mg and increased gradually until 
the maximum dose of 2g/day. 
Valsartan started at a dose of 1 x 80 mg, 
the dose increased when the target 
blood pressure has not been reached. 
Patients control and equipped with 
drugs every 4 weeks. The incidence of 
drug side effects noted. 
After the completion of the treatment 
blood samples to assess HOMA-IR 
end. Patients were asked to record the 
diet consumed, then do calorie 
counting. Dietary conducted by 
nutritionist suitable diet according to 
the guidelines PERKENI 2011. 
Patients were asked to record the diet 
for at least 3 days in 4 weeks. 
 
Result 
After 11 months only got 15 
subjects who meet the inclusion and 
exclusion criteria. This amount meets 
43% of the samples are expected. All 
subjects followed the procedure until 
the study is completed. The research 
subjects consisted of male subjects as 
many as six people (40%) and women 
were nine people (60%) aged between 
43-63 years with an average of 56.26 ± 
5.35 years. The basic characteristics of 
15 patients with Metabolic Syndrome 
with NAFLD before the therapy can be 
seen in Table 1, and after treatment in 
Table 2. 
 
 
 
Table 6 base characteristic 15 metabolic syndrome patients with NAFLD before therapy 
 
Variable Mean ± SD Median Min/Max 
Normality test (p) 
Kolmogorov-Smirnov4 Shapiro-Wilk 
Systolic pressure, 
mmHg 123.33±8.16 120 110:140 .008 .049 
Diastolic pressure, 
mmHg 78.00±5.60 80 70:90 .000 .001 
Body Mass Index 
(BMI) 28.23±3.03 27.78 24.56:33.78 .122 .131 
AST 23.20±7.19 24 15:43 .155 .026 
ALT 24.73±11.70 20 8:46 .148 .345 
GGT 34.00±18.30 31 12:77.0 .200* .033 
Homa-IR 3.77±3.98 2.8 60:14.50 .003 .001 
LP, cm (male) 94.66±8.35 96.5 83:105 .200 .756 
LP, cm (female) 99.00±8.29 97 89:110 .200 .199 
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Table 7 Base characteristic 15 metabolic syndrome patients with NAFLD before therapy 
 
 
Description: 
A: Correction Lillie for significance. 
*: The lower limit of a significant value 
AST: aspartate aminotransferase 
ALT: alanine aminotransferase 
GGT: Gamma-glutamyltransferase 
LP: Waist circumstance 
 
 
 
 
From the above explanation that 
the average value of HOMA-IR before 
and after therapy, which illustrated by the 
following graph (Figure 1). 
 
Figure 1. Graph of mean HOMA-IR before and 
after therapy 
 
 
Discussion 
 
This study cannot prove that 
administration of metformin and valsartan 
in patients with metabolic syndrome with 
NAFLD would improve insulin resistance 
assessed by the HOMA-IR method. On 
average HOMA-IR at the end of the 
treatment is higher than before treatment 
(Figure 1). Another parameter test results 
also showed an increase in value at the 
end of the treatment, only the value of 
AST are lower in the examination at the 
end of the treatment. AST but the decline 
is not statistically significant. Four of the 
fifteen (26%) samples showed a decrease 
in HOMA-IR but no decline that reached 
a value below two, the cut-off for the 
pathological condition of insulin 
resistance. 
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Variable Mean ±SD Median Min/max 
Normality test (p) 
Kolmogorov-Smirnov4 Shapiro-Wilk 
systolic pressure, mmHg 125±11.02 125 .200* .208 .208 
diastolic pressure, mmHg 82.66±7.76 80 .026 .96 .096 
Body Mass Index (mmHg) 28.12±2.82 27.08 .146 .075 .075 
AST 21.53±8.20 20 .200* .027 .027 
ALT 22.93±11.38 23 .200* .750 .750 
GGT 35.26±20.71 26 .003 .004 .004 
Homa-IR 5.03±3.59 3.79 .144 .022 .022 
LP, cm (male) 95.41±5.37 96.5 .089 .075 .075 
LP, cm (female) 100.66±6.36 101 .200* .509 .509 
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The results that were largely not in 
line with the concept of the study 
according to the researchers this caused 
mainly due to the samples obtained are 
not representative of the population to be 
observe. Both are the weakness of the 
study. 
There are four reasons why the 
samples were not representative of the 
population to be observed. First, the 
number of samples is too little. Second, 
43% of the target sample size. Then, the 
data obtained from the sample is not 
homogeneous. The last, there are 
variations in the value of a very wide and 
the conditions are not naturally form were 
on insulin treatment. 
The sampling method used in this 
study convenience sampling, to the limit, 
just acquired 15 research subjects or meet 
43% of the large sample desired. This will 
affect the internal validity of the study 
because the sample obtained is not 
representative of the population target.8 
The number of samples that do 
not fit this target also has an effect on the 
distribution of the data obtained; most of 
the data obtained are not normally 
distributed. Although there is a statistical 
method that can analyze the data were not 
normally distributed, but the results are 
not as good when using distributed data 
normal.8 
Very wide variation value as the 
initial value of HOMA-IR research lows is 
0.6 while the highest value of 14.5 
indicates as an heterogeneous data (not 
homogeneous). Data are not 
homogeneous either cannot be 
represented by a set of data.8 
Sampling sites considered the 
main cause of acquired samples are less 
representative of the population to be 
observed. Research survey in the United 
States stated that complaints were made 
with metabolic syndrome come to the 
doctor is overweight, this complaint 
theoretically and regulations more easily 
found or complaints in health facilities 
primer.9 The results of the survey also 
revealed that cases of metabolic syndrome 
are also more many found in urban areas 
compared to rural areas. 
This research data is partial data 
from a study that designed to do in a 
referral hospital type A Dr. Sardjito 
Hospital. The study, entitled The Effect 
of Metformin and Metformin compared 
Telmisartan in Lowers Fatty Liver in 
Obese Diabetic Mellitus and 
Hypertension. 
Unnatural condition is also 
present in all the samples in the form of 
all subjects was erect suffering from 
diabetes and is on insulin therapy into its 
own weaknesses of this study. Sampling 
sites at referral hospitals type A return is 
considered to be the cause of this 
condition because DM is the most 
accepted referral cases poly 
endocrinology. 
DM patients included in this study 
is justified because the criteria for 
metabolic syndrome used is the IDF 
(2006).10 The metabolic syndrome is more 
precise to mention the concept rather 
than a diagnosis, many organizations are 
proposing the criteria for metabolic 
syndrome. Organizations that adhered to 
the concept that metabolic syndrome a 
pre-diabetic condition is certainly not 
going to enter into a group with diabetes 
mellitus metabolic syndrome. IDF is a 
concept that metabolic syndrome is a 
cluster of health problems that are 
increasing the risk of disease heart and 
vascular so the inclusion of people with 
DM in the criteria for metabolic 
syndrome. 
Use of insulin in all subjects 
regarded as a weakness of the study, in 
addition to the calculation of the HOMA-
IR based on measurements of blood 
insulin levels, but also because of the 
amount of insulin that used by each 
individual changes. 
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Wallace et al, on the results of the 
review actually allow the use of HOMA-
IR method for evaluating insulin 
resistance in individuals who are on 
insulin therapy but with a record of the 
patient's condition is stable, which means 
the dose of insulin that is used does not 
changes.11  Insulin dosage obtained the 
subject of this research is still changing 
but the change of insulin dose is not 
specifically analyzed. 
Owen and Robert proved that 
cross-react exogenous insulin analog in 
the measurement of endogenous insulin 
levels with five tools immunoassay 
berbeda.12 Li et al. proposed the use of C-
peptide values for the calculation of 
HOMA-IR. The C-peptide value 
proportional to the levels of endogenous 
insulin. C-peptide is a proinsulin.13 
Modification fragment of the formula: 
Homa-IR (CP) = 1.5 + x fasting glucose 
fasting levels of C-peptide/2800. 
Changes in blood glucose and 
insulin levels also influenced by diet and 
physical activity. This variable cannot be 
completely controlled, study subjects 
received nutrition education and 
motivation of physical training of 
educators before the study and were 
evaluated every month during a visit to 
the clinic. At the end of the study to 
evaluate, the patients' adherence to the 
diet recommended by the way food recall. 
Researchers did not make an assessment 
of the physical activity the subject of 
research to be biased against the results of 
this study. Another confounding factor is 
the use of drugs such compliance is not 
controlled. 
Use of metformin for metabolic 
syndrome remains controversial, until 
today this drug has not officially 
recommended in the metabolic syndrome 
in the American containment procedures. 
Unity Internal Medicine Indonesia also 
not recommends this therapy despite 
insulin resistance has agreed with an 
underlying condition syndrome 
metabolic.14 
Systematic review of five studies 
randomized control trial (RCT) about the 
benefits of metformin in obese patients 
conducted Park et al. concluded that the 
short-term metformin therapy was shown 
to improve insulin resistance in a 
moderate in the younger age group.15 
From the data, the average age of 
subjects, of this study included older age 
group, 56.26 years. 
Dosing metformin different as 
accepted by the subjects of this study 
cannot explain the results of this study are 
unfavorable, research Oy et al. proved 
that there should be improvement of 
insulin resistance by receiving metformin 
even low dose (250mg per day) .16 
Research Bahadir et al., and Sarac 
et al. get a result like this research that 
provision does not fix HOMA IR 
valsartan in hypertensive patients with the 
syndrome metabolik.17, 18 While research 
DeRosa et al. showed that valsartan 
administration for 12 weeks in diabetic 
patients with the metabolic syndrome can 
improve blood pressure and levels of 
HOMA IR.19  
Research Vitale et al. showed that 
telmisartan given to patients with 
metabolic syndrome would improve 
resistance parameter insulin.20 
A meta-analysis conducted Takagi 
and Umemoto that compared the drugs in 
the ARB class effect of improving insulin 
resistance conclude that the only proven 
telmisartan significantly improved 
resistance insulin.21 
 
Conclusion 
This study does not prove that 
administration of metformin and valsartan 
in patients with metabolic syndrome with 
NAFLD would improve insulin resistance 
assessed by HOMA-IR method. 
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